Table 1. Immune Checkpoint Inhibitors Approved by the US Food and Drug Administration (FDA).

From: Mechanisms and Management of Immune Checkpoint Inhibitor-Related Cardiac Adverse Events

Immune checkpoint inhibitors Product name Target Approved indication by the FDA Date of approval
Ipilimumab Yervoy CTLA-4 Melanoma, renal cell carcinoma, colorectal cancer March 2011
Pembrolizumab Keytruda PD-1 Melanoma, non-small cell lung cancer, non-squamous cell lung cancer (with high PD-L1 expression), renal cell carcinoma, classic Hodgkin's lymphoma, gastric or gastroesophageal junction adenocarcinoma, urothelial carcinoma, cervical cancer, large B-cell lymphoma, Merkel cell carcinoma September 2014
Nivolumab Opdivo PD-1 Melanoma, non-small cell lung cancer, small cell lung cancer, renal cell carcinoma, Hodgkin’s lymphoma, head and neck squamous cell carcinoma, hepatocarcinoma, colorectal cancer December 2014
Avelumab Bavencio PD-L1 Merkel cell carcinoma, urothelial carcinoma, renal cell carcinoma November 2015
Atezolizumab Tecentriq PD-L1 Urothelial carcinoma, non-small cell lung cancer, breast cancer, non-squamous non-small cell lung cancer, small-cell lung cancer May 2016
Durvalumab Imfinzi PD-L1 Urothelial carcinoma, non-small cell lung cancer February 2016
Cemiplimab Libtayo PD-1 Cutaneous squamous cell carcinoma September 2018